80% of US Factories Have No Automation as Medtech Surges Ahead

The automation divide

Eighty percent of U.S. manufacturing facilities currently operate with zero automation, according to figures cited by Intrinsic Chief Technology Officer Brian Gerkey and reported by Manufacturing Dive in May 2026. The statistic quantifies a capability gap that procurement and operations leaders increasingly see reflected in hiring costs, throughput inconsistency, and supply chain vulnerability.

The problem is not awareness. Jeff Burnstein, president of the Association for Advancing Automation, told Manufacturing Dive that interest in AI and automation runs high across manufacturing sectors, but execution remains the bottleneck. His organization's research shows a strong majority of manufacturers believe AI will be critical to their future competitiveness, yet only a small percentage report widespread deployment today.

Deloitte's 2025 Smart Manufacturing and Operations Survey found that 92% of manufacturers surveyed believe smart manufacturing will be the main driver of competitiveness over the next three years. The gap between that conviction and actual implementation represents the central operational challenge facing manufacturing leadership.

Why it matters

This widening automation gap will determine which manufacturers can meet quality requirements, manage labor shortages, and maintain supply chain resilience over the next three years. Companies that deploy targeted automation now will set the process benchmarks against which competitors are measured—particularly as regulatory and margin pressures make manual processes increasingly difficult to defend.

Medtech moves on precision and compliance

While the broader manufacturing base hesitates, medical device manufacturers are making concrete automation investments tied to specific quality and compliance requirements. MDDI Online's 2026 coverage tracks several notable moves.

Cordica Medical's acquisition of RapidWerks, reported by David Hutton in MDDI Online, brings micro-molding capabilities in-house. Micro-molding for medical components demands micron-level tolerances and full traceability—requirements that make manual or legacy processes difficult to defend to quality auditors. The acquisition compresses the supply chain and tightens process control.

Separately, hospital care product manufacturers are replacing adhesive and mechanical joining methods with automated ultrasonic welding processes, according to MDDI Online coverage. Ultrasonic welding produces hermetic, repeatable bonds without consumables, and the join cycle is fast enough to integrate into high-volume assembly lines.

Ranpak's collaboration with Medline, also covered by MDDI Online, applies automation to packaging and fulfillment for medical supply distribution. The partnership addresses manual labor reduction in fulfillment operations handling thousands of SKUs under tight delivery and sterility requirements.

Inline measurement closes the quality loop

Automation without inline measurement still relegates quality control to end-of-line inspection, finding defects only after cost has been incurred. LaserLinc's precision measurement advances, highlighted in MDDI Online's sponsored coverage, address setup time and in-process accuracy for medical tubing and similar extruded components. Faster setup directly reduces changeover cost on short production runs, which are standard in medical device manufacturing.

This cluster of medtech activity follows a different model than the AI-heavy automation narrative dominating investor conversations. In medical devices, automation investment tends to be narrow, traceable, and tied to a specific compliance or quality outcome—an approach easier to validate with regulators and justify in capital approval processes.

Why most manufacturers lag

Manufacturing Dive's reporting identifies several structural barriers keeping most U.S. manufacturers at zero automation. Capital cost remains the most cited obstacle, particularly for small and mid-size facilities that lack the volume to amortize equipment quickly. Integration complexity follows closely: older factories were not designed for automated systems, and retrofitting them requires engineering resources many companies do not have on staff.

The contrast with medtech is partly a function of margin and regulatory pressure. Device manufacturers face FDA documentation requirements and quality system mandates that make automated, traceable processes a near-necessity at scale. That same pressure becomes a forcing function for investment that general manufacturers rarely face.

The Deloitte survey figure bears repeating for operations leaders evaluating their own timelines: 92% of peers believe smart manufacturing is a competitive prerequisite within three years, yet the installed base of automation remains thin. The companies that close that distance first—through targeted acquisitions, supplier collaborations, or incremental inline technology—will set the process benchmarks others will be measured against.

These details were first reported by Manufacturing Dive and MDDI Online.